Acumen pharmaceuticals to participate in the ubs global healthcare conference

Newton, mass., nov. 06, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the ubs global healthcare conference on wednesday, nov. 13, 2024, at 1:15 p.m. pt (4:15 p.m. et).
ABOS Ratings Summary
ABOS Quant Ranking